Updated Jul 16, 2026
Karydas Daphne has filed 2 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $150K.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-18 | MLYS | Mineralys Therapeutics, Inc. | S — Open-market sale | 3.0K | $25.00 | $75K |
| 2026-06-18 | MLYS | Mineralys Therapeutics, Inc. | M — Option exercise | 3.0K | $12.02 | $36K |
| 2026-04-02 | MLYS | Mineralys Therapeutics, Inc. | S — Open-market sale [10b5-1] | 3.0K | $25.00 | $75K |
| 2026-04-02 | MLYS | Mineralys Therapeutics, Inc. | M — Option exercise [10b5-1] | 3.0K | $12.02 | $36K |
| 2026-02-21 | MLYS | Mineralys Therapeutics, Inc. | A — Grant or award | 6.2K | $0.00 |
Karydas Daphne is a corporate insider — currently tracked as Director of Mineralys Therapeutics, Inc. (MLYS). InsiderAlpha tracks every SEC Form 4 filing in real time.
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($150K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Karydas Daphne profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.